News

Shape the Strategic Direction of Genomic Medicine at CRISPRMED26

The CRISPRMED26 Conference in Copenhagen, April 2026, is fast becoming the leading global forum for CRISPR and genomic medicine, and a premier platform to showcase your company’s commitment to advancing the field

- Nov. 20, 2025
News

The CRISPRMED26 Conference in Copenhagen, April 2026, is fast becoming the leading global forum for CRISPR and genomic medicine, and a premier platform to showcase your company’s commitment to advancing the field.

We warmly welcome our confirmed sponsors, whose early support is helping shape this high-level event:

Atrandi Biosciences, Aldevron , Integrated DNA Technologies, Agilent Technologies, Ampliqon A/S, Axolabs , BioSpring GmbH, ChemoMetec, Hongene Biotech Corporation, Lonza, Mission Bio, Synthego , ST PHARM, and VectorBuilder.

A few high-impact sponsorships remain - more than logo placement, they are a strategic investment in access and influence:

  • High-Impact Visibility - Feature exposure across CRISPR Medicine News and CRISPRMED26 channels (35k readers/month, +30k followers, +20k subscribers), plus visibility throughout the conference and satellite meetings.

  • Quality Connections - Direct access to 500+ leaders from research, industry, regulation, clinics, and patient organisations across 40+ countries.

  • Strategic Brand Alignment - Align with the world’s largest CRISPR medicine conference and the official public launch of the European Genomic Medicine Consortium (EGMEDC).

We want your expertise to move science forward. Let us create a package to your goals and secure your high-profile presence.

Email our team at: info@crisprmedicineconference.com for the sponsor prospectus.

Tags

HashtagArticleHashtagNewsHashtagCRISPRMED26

CLINICAL TRIALS
Non-small Cell Lung Cancer, NSCLC, (NCT06097962)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastric Cancer and Colorectal Cancer, CRC, (NCT07166263)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine